Invitae vs 23andMe Which Offers More Value?

Invitae and 23andMe are two prominent companies in the rapidly growing genetic testing industry. Both companies offer consumers a way to access information about their genetic makeup, but they have distinct business models and target different markets. While 23andMe focuses on direct-to-consumer genetic testing kits for ancestry and health purposes, Invitae provides genetic testing services primarily to healthcare providers. Investors may consider factors such as revenue growth, market opportunities, and regulatory challenges when comparing these two stocks.

Invitae or 23andMe?

When comparing Invitae and 23andMe, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Invitae and 23andMe.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Invitae has a dividend yield of -%, while 23andMe has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Invitae reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, 23andMe reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Invitae P/E ratio at -0.00 and 23andMe's P/E ratio at -0.14. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Invitae P/B ratio is -0.00 while 23andMe's P/B ratio is 0.84.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Invitae has seen a 5-year revenue growth of 0.00%, while 23andMe's is -0.98%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Invitae's ROE at 178.89% and 23andMe's ROE at -303.43%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.00 for Invitae and $3.27 for 23andMe. Over the past year, Invitae's prices ranged from $0.00 to $1.66, with a yearly change of 331820.00%. 23andMe's prices fluctuated between $2.65 and $20.20, with a yearly change of 660.83%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.